Previous 10 |
home / stock / bioyf / bioyf news
BioSyent ( OTCPK:BIOYF ): Q2 GAAP EPS of C$0.11. More news on: BioSyent Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
BioSyent Inc (BIOYF) Q1 2018 Results Conference Call May 30, 2018 08:00 AM ET Executives Rene Goehrum - President & CEO Presentation Rene Goehrum Hello, and welcome to the Q1 2018 Results Presentation. My name is Rene Goehrum and I’m the President and CEO of BioS...
The following slide deck was published by BioSyent Inc. in conjunction with their 2018 Q1 earnings Read more ...
BioSyent ( OTCPK:BIOYF ): Q1 EPS of C$0.08 More news on: BioSyent Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
BioSyent ( OTCPK:BIOYF ): Q4 EPS of $0.10 More news on: BioSyent Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
The Business BioSyent is a Canadian specialty pharmaceutical company focused on sourcing, commercializing, and further develop niche pharmaceutical and healthcare products with peak sales of <$20 million that are not yet available in Canada but is commercialized in other countrie...
News, Short Squeeze, Breakout and More Instantly...
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a Euro...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: Return on Equity for TTM March 31, 2024 was 21% as compared to 15% ...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 20...